

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

9C02240		315648
Licensee		In accordance with letter dated August 15, 2006 and September 13, 2006,
1. InnerVision Advanced Medical Imaging Center LLC,		3. License number 13-32273-01 is amended in its entirety to read as follows:
2. 3801 Amelia Avenue Suite A Lafayette, IN 47905		4. Expiration date November 30, 2010
		5. Docket No. 030-35552 Reference No.
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed one curie of iodine-131)
D. Iodine-125, as permitted by 10 CFR 35.1000	D. Liquid as Iotrex™	D. 8.0 curies
9. Authorized Use:		
A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.		
B. Any imaging and localization study permitted by 10 CFR 35.200.		
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.		
D. For medical use permitted by 10 CFR 35.1000, in the Cytoc Surgical Products Gliasite® Radiotherapy System.		

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 3801 Amelia Avenue, Lafayette, Indiana.
11. The Radiation Safety Officer for this license is John Fiederlein, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-32273-01Docket or Reference Number
030-35552

Amendment No. 07

11. The Radiation Safety Officer for this license is John Fiederlein, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Alexander G. Boutselis, M.D.	10 CFR 35.100, 35.200 and 35.300.
Steven B. Jones, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
John F. Fiederlein, M.D.	10 CFR 35.100, 35.200 and 35.300.
Irene C. Gordon, M.D.	10 CFR 35.300.
Stephen J. Matthews, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding thyroid carcinoma therapy).
Deborah Wright, M.D.	10 CFR 35.200.
Adel Yaacoub, M.D.	10 CFR 35.200.
Paul DesRosiers, M.D.	Iodine-125 in the Cytoc Surgical Products GliaSite® Radiotherapy System.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-32273-01Docket or Reference Number
030-35552

Amendment No. 07

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated October 2, 2000;
- B. Fax transmittals dated November 13, 2000, June 9, 2006; and
- C. Letters dated November 16, 2005, February 7, 2006, May 12, 2006, August 15, 2006 and September 13, 2006.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 09 2006By *Toye L. Simmons*
Toye L. Simmons
Materials Licensing Branch
Region III